Drug Information

Drug (ID: DG01727) and It's Reported Resistant Information

• Name: JQ1/Osimertinib
• Synonyms: JQ1/Osimertinib
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [1]

• Molecule Alteration: IF-insertion; p.Y772_A775dupYVMA (c.2325_2326insTATGTAATGGCA)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Ba/F3 cells; Colon; Homo sapiens (Human); CVCL_0161
• In Vitro Model: NCI-H1781 cells; Pleural effusion; Homo sapiens (Human); CVCL_1494
• Experiment for Molecule Alteration: Western blotting analysis; Immunohistochemistry; H&E staining assay
• Experiment for Drug Resistance: CCK-8 assay

References

• Ref 1: Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with OsimertinibClin Cancer Res. 2018 Jun 1;24(11):2594-2604. doi: 10.1158/1078-0432.CCR-17-1875. Epub 2018 Jan 3.